Bilous N, Abramenko I, Kryachok I, Bazyka D, Chumak A, Bebeshko V
Scientific Research Centre for Radiation Medicine, AMS of Ukraine, Kyiv, Ukraine.
Exp Oncol. 2005 Dec;27(4):325-9.
The aim of this study was to evaluate significance of VH mutation status for prognosis of B-cell chronic lymphocytic leukemia (B-CLL) patients in comparison with other prognostic markers.
The VH mutation status was evaluated in 43 B-CLL patients by RT-PCR amplification and nucleotide sequencing, and CD38 expression - by two-color FACS analysis. The prognostic influence of VH mutation rate and CD38 expression level was tested by different statistical methods.
The increasing number of advanced cases over the follow-up period, shorter median time from diagnosis to start of second line therapy, worse response to fludarabine treatment, poor survival for early stages B-CLL were found in unmutated versus mutated CLL patients. The significance of CD38 expression for CLL prognosis was revealed as predictor for response for fludarabine treatment and time of progression in advanced stages. The correlation between CD38 expression and VH mutation status was not found.
Simultaneous determination of VH mutation status and CD38 expression may be helpful for prediction of CLL prognosis.
本研究旨在评估与其他预后标志物相比，VH突变状态对B细胞慢性淋巴细胞白血病（B-CLL）患者预后的意义。
通过逆转录聚合酶链反应（RT-PCR）扩增和核苷酸测序对43例B-CLL患者的VH突变状态进行评估，通过双色荧光激活细胞分选（FACS）分析评估CD38表达。采用不同统计方法检测VH突变率和CD38表达水平的预后影响。
在未发生突变与发生突变的慢性淋巴细胞白血病（CLL）患者中发现，随访期间晚期病例数量增加，从诊断到开始二线治疗的中位时间缩短，对氟达拉滨治疗的反应较差，早期B-CLL患者生存率较低。CD38表达对CLL预后的意义在于，它可作为氟达拉滨治疗反应和晚期疾病进展时间的预测指标。未发现CD38表达与VH突变状态之间存在相关性。
同时测定VH突变状态和CD38表达可能有助于预测CLL预后。
